Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Deals & M&A

Jasper Therapeutics nears first renal-study readout after July acquisition and $132m raise

The US biotech ended September with $135.3m in cash and expects its first interim kidney data for vensobafusp alfa before the end of the year.

16 Nov 2026 · Jasper Therapeutics, Inc. JSPR · Company news

Jasper Therapeutics ended the third quarter with $135.3m in cash. The company has completed two July transactions that reshaped its balance sheet: an all-stock acquisition of Kira Pharmaceuticals and a private placement of preferred stock worth about $132.0m. It disclosed the figures alongside its quarterly results on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Deals & M&AAll →